In recent years, the popularity of compounded peptides has become widespread, largely thanks to the social media spotlight.
One cannot open a social media app without seeing something about GLP-1s or, more broadly, their cousin peptides, used in a variety of applications in longevity and sports medicine.
Peptides — in part due to their physiochemical structure, accessibility, regulatory status and use in professional practice — historically occupied a relatively niche, unregulated place in American medicine where curious folks could self-experiment with protocols to better their overall health.
But the current and prior administration's views on peptides differed dramatically, and today, the policy landscape for peptides is undergoing a significant shift.
Recent public discourse, podcast fodder and high-level policy signals now clearly indicate that the black and gray market era of peptides is reaching a tipping point into what is largely expected to be a government-sanctioned program for the manufacturing and distribution of peptides for personal consumption.
Read more here.